INT56251

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.38
First Reported 1994
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 8
Disease Relevance 3.16
Pain Relevance 0.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (NBN) nucleolus (NBN) chromosome (NBN)
nucleus (NBN) intracellular (NBN) cell cycle (NBN)
Anatomy Link Frequency
plasma 2
brain 1
intestine 1
NBN (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 2 98.76 Very High Very High Very High
Dopamine 2 98.48 Very High Very High Very High
fortral 6 95.64 Very High Very High Very High
positron emission tomography 2 94.08 High High
Bioavailability 5 5.52 Low Low
Potency 25 5.00 Very Low Very Low Very Low
tolerance 20 5.00 Very Low Very Low Very Low
abdominal pain 5 5.00 Very Low Very Low Very Low
beta blocker 5 5.00 Very Low Very Low Very Low
withdrawal 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyperbilirubinemia 108 100.00 Very High Very High Very High
Toxicity 15 99.48 Very High Very High Very High
Disorder Of Lipid Metabolism 81 98.88 Very High Very High Very High
Jaundice 32 96.50 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 342 88.76 High High
Syndrome 10 77.48 Quite High
Hepatitis C Virus Infection 15 75.84 Quite High
Hemolytic Anemia 5 67.20 Quite High
Infection 43 66.40 Quite High
Chronic Hepatitis 15 65.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In contrast, significantly lower rebound rates were recognized for ATV versus comparator PI groups in the subset of patients with prior exposure to unboosted PIs (5% versus 22%; p < 0.001).
ATV Binding (recognized) of
1) Confidence 0.38 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.31 Pain Relevance 0
Jaundice is infrequent (<10%) and excessive bilirubin elevations leading to ATV discontinuation are rare (around 1% of treated patients).1 The risk for hyperbilirubinemia seems to be associated to ATV plasma levels, and is more frequent when high doses of ATV are given (ie, 600 mg qd) or when ATV is boosted with r.9,25,29,30 Of note, hyperbilirubinemia is completely reversible after stopping ATV.
ATV Binding (associated) of in plasma associated with hyperbilirubinemia and jaundice
2) Confidence 0.29 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.67 Pain Relevance 0
After 48 weeks, patients who switched to ATV showed significantly fewer total cholesterol, fasting triglyceride, and non-HDL cholesterol elevations than did patients in the comparator PI group (p < 0.001).
ATV Binding (switched) of associated with disorder of lipid metabolism
3) Confidence 0.29 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.39 Pain Relevance 0
Therefore, the combination in homozygosis at *28, UGT1A7-57G, UGT1A3-66C and UGT1A7 was identified as highly predictive of severe hyperbilirubinemia under ATV therapy.41

Toxicity

ATV Binding (hyperbilirubinemia) of associated with toxicity and hyperbilirubinemia
4) Confidence 0.29 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.65 Pain Relevance 0
Several studies have found an association between ATV plasma concentrations and serum bilirubin levels.9,25,29,30 However, at this time there are not enough data available to define threshold for scleral jaundice, which otherwise may vary from one subject to another, although it can generally be recognized when serum bilirubin goes up 2.5 mg/dL.
ATV Binding (association) of in plasma associated with jaundice
5) Confidence 0.29 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697529 Disease Relevance 0.58 Pain Relevance 0
Inclusion of a 100-mg dose of ritonavir was important in the ATV regimen to counteract the previously documented TDF-related 23% reduction in ATV Cmin and 25% reduction in ATV exposure that is believed to be due to a physicochemical interaction of ATV and TDF in the intestine [26].
ATV Binding (interaction) of in intestine
6) Confidence 0.26 Published 2008 Journal AIDS Res Ther Section Body Doc Link PMC2365957 Disease Relevance 0.56 Pain Relevance 0
A blocking dose of the dopamine D2 antagonist spiperone (1 mg/kg) did not significantly inhibit [C-11]-(+)-NBnNM binding.
NBnNM Binding (binding) of associated with dopamine and antagonist
7) Confidence 0.01 Published 1994 Journal Life Sci. Section Abstract Doc Link 8072384 Disease Relevance 0 Pain Relevance 0.31
Thus, [C-11]-(+)-NBnNM binds with high specificity and selectivity to sigma receptors in vivo and offers excellent potential to study sigma receptors in living human brain via positron emission tomography.
NBnNM Binding (binds) of in brain associated with positron emission tomography
8) Confidence 0.01 Published 1994 Journal Life Sci. Section Abstract Doc Link 8072384 Disease Relevance 0 Pain Relevance 0.30

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox